0001104659-20-087480.txt : 20200728
0001104659-20-087480.hdr.sgml : 20200728
20200728183332
ACCESSION NUMBER: 0001104659-20-087480
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200728
FILED AS OF DATE: 20200728
DATE AS OF CHANGE: 20200728
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: RA CAPITAL MANAGEMENT, L.P.
CENTRAL INDEX KEY: 0001346824
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39397
FILM NUMBER: 201055122
BUSINESS ADDRESS:
STREET 1: 200 BERKELEY STREET, 18TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: 617-778-2500
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET, 18TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER NAME:
FORMER CONFORMED NAME: RA CAPITAL MANAGEMENT, LLC
DATE OF NAME CHANGE: 20051213
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kolchinsky Peter
CENTRAL INDEX KEY: 0001384859
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39397
FILM NUMBER: 201055123
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 18TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Shah Rajeev M.
CENTRAL INDEX KEY: 0001619841
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-39397
FILM NUMBER: 201055124
MAIL ADDRESS:
STREET 1: 200 BERKELEY STREET
STREET 2: 18TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Inozyme Pharma, Inc.
CENTRAL INDEX KEY: 0001693011
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 475129768
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
BUSINESS PHONE: 857-330-4340
MAIL ADDRESS:
STREET 1: 321 SUMMER STREET
STREET 2: SUITE 400
CITY: BOSTON
STATE: MA
ZIP: 02210
FORMER COMPANY:
FORMER CONFORMED NAME: Inozyme Pharma, LLC
DATE OF NAME CHANGE: 20161222
4
1
tm2025929-1_4.xml
OWNERSHIP DOCUMENT
X0306
4
2020-07-28
1
0001693011
Inozyme Pharma, Inc.
INZY
0001346824
RA CAPITAL MANAGEMENT, L.P.
200 BERKELEY STREET, 18TH FLOOR
BOSTON
MA
02116
0
0
1
0
0001384859
Kolchinsky Peter
C/O RA CAPITAL MANAGEMENT, L.P.
200 BERKELEY STREET, 18TH FLOOR
BOSTON
MA
02116
0
0
1
0
0001619841
Shah Rajeev M.
C/O RA CAPITAL MANAGEMENT, L.P.
200 BERKELEY STREET, 18TH FLOOR
BOSTON
MA
02116
0
0
1
0
Common Stock
2020-07-28
4
C
0
1403653
A
1403653
I
See footnote
Common Stock
2020-07-28
4
P
0
600000
16
A
2003653
I
See footnote
Series A-2 Convertible Preferred Stock
2020-07-28
4
C
0
10489510
D
Common Stock
1403653
0
I
See footnote
The Series A-2 Convertible Preferred Stock converted into Common Stock on a 7.4730-for-one basis upon the closing of the Issuer's initial public offering.
These securities include (a) 1,041,757 shares held by RA Capital Healthcare Fund, L.P. (the "Fund"), (b) 186,440 shares held by a separately managed account (the "Account"), and (c) 175,456 shares held by RA Capital Nexus Fund, L.P. (the "Nexus Fund").
RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund, the Account, and the Nexus Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members.
The Adviser, the Adviser GP, Dr. Kolchinsky, and Mr. Shah may be deemed indirect beneficial owners of the reported securities for purposes of Section 13(d) of the Securities Exchange Act of 1934 (the "Act"). They disclaim beneficial ownership of any of the reported securities for the purpose of determining whether they are subject to Section 16 of the Act, however, in reliance on Rule 16a-1(a)(1)(v) and (vii). To the extent that they might be deemed subject to Section 16, they disclaim beneficial ownership of securities held by the Fund or the Nexus Fund for purposes of Rule 16a-1(a)(2), except to the extent of their pecuniary interest therein, and disclaim any pecuniary interest in securities held in the Account for purposes of Rule 16a-1(a)(2).
Includes (a) 513,501 shares held by the Fund, (b) 55,311 shares held by the Account, and (c) 31,188 shares held by the Nexus Fund, in each case acquired in the Issuer's initial public offering.
Includes (a) 1,555,258 shares held by the Fund, (b) 241,751 shares held by the Account, and (c) 206,644 shares held by the Nexus Fund.
/s/ Peter Kolchinsky, Manager of RA Capital Management, L.P.
2020-07-28
/s/ Peter Kolchinsky, individually
2020-07-28
/s/ Rajeev Shah, individually
2020-07-28